| PB-0006 | PB0006 - Association of catestatin levels with prothrombotic state in peripheral vascular disease | Oleksii Korzh | |
| PB-0041 | PB0041 - Symptomatic Ischemic Stroke in Lung Cancer Patients with Subclinical Infarctions on Staging MRI | Avi Leader | |
| PB-0045 | PB0045 - Using data-trained neural networks of platelet phenotypes to simulate thrombosis under stenotic flow | Scott Diamond | |
| PB-0057 | PB0057 - Diagnostic performance of commercial antithrombin activity assays: do we get what we expect? | Christelle Orlando | |
| PB-0065 | PB0065 - Evaluating DIC resolution as a surrogate outcome for mortality in sepsis-associated DIC | Tomoki Tanigawa | |
| PB-0066 | PB0066 - Evaluating the Risk of Thrombosis Associated with Protein C Deficiency Using Population-Scale Data | Alfonso Rodriguez Espada | |
| PB-0072 | PB0072 - Germline Loss of Function in SERPING1 (C1 Inhibitor) is a Multi-Phenotypic Thrombotic Disorder | Alfonso Rodriguez Espada | |
| PB-82 | PB0082 - Inhibitory mechanisms of a tick salivary serpin on human haemostasis | Ingrid Dijkgraaf | |
| PB-0084 | PB0084 - Investigating the Mechanisms of ADAMTS13 Metalloprotease Domain Latency | Peter Andrisani | |
| PB-0086 | PB0086 - Large scale unbiased proteomics uncovers novel pathways and biomarkers for VWD Type 1 | Brooke Sadler | |
| PB-0089 | PB0089 - Modulating Endothelial Thromboinflammation Biomarkers in Diabetic Convalescent COVID-19 Patients | Alejandro gonzalez ochoa | |
| PB-0112 | PB0112 - The Clinical Utility of ADAMTS-13 Testing: An Audit of Assay Requests in a Tertiary hospital | Ghadah Al yami | |
| PB-119 | PB0119 - Two Phase 3 studies on antithrombin concentrate in congenital and acquired antithrombin deficiency | Sarah Baker | |
| PB-0120 | PB0120 - Unveiling the Impact of Antithrombin Levels in Heparins Anticoagulant Effect: An In Vitro Analysis | Eugenio Rosado | |
| PB-0123 | Von Willebrand factor A1 blockade prevents platelet-mediated reocclusion in a microfluidic model of arterial thrombosis | Ronit Kar | |
| PB-0124 | PB0124 - Von Willebrand Factor and ADAMTS13 in major adverse limb events in peripheral artery disease | Vinai Bhagirath | |
| PB-128 | PB0128 - Accurate measurement of edoxaban concentration after reversal by andexanet alpha | Sho Shinohara | |
| PB-0130 | PB0130 - Advancing Understanding of Cellular Deposition and Thrombosis in Extracorporeal Oxygen Therapy | Tyler Hughes | |
| PB-0144 | PB0144 - Clot waveform analysis in patients with hemophilia A B and their related disease | Teruhisa Fujii | |
| PB-0147 | PB0147 - Comparative study of four platelet function tests calculated through two techniques | Tasuku Sakayori | |
| PB-158 | PB0158 - Effect of Mim8 and Emicizumab on Factor VIII Recovery by a Novel Bovine Chromogenic FVIII Assay | Elaine Benoit | |
| PB-0169 | PB0169 - Impact of factor VIII activity chromogenic assay in the diagnosis of mild hemophilia A | Virginie Barbay | |
| PB-171 | PB0171 - Impact of Underfilled Samples from Three Tube Manufacturers on Coagulation Laboratory Tests | Lee Beckett | |
| PB-0172 | PB0172 - Improved APTT correlation with anti-Xa and anti-IIa using heparin resistant recalcification | stephen macdonald | |
| PB-176 | PB0176 - Method comparison study of activated partial thromboplastin time reagents | Jordan Jones | |
| PB-0184 | PB0184 - Platelet Function Testing in Fresh vs. Shipped Blood Samples Under Real-World Conditions | ANA MARIN QUILEZ | |
| PB-0186 | PB0186 - Prediction of Perioperative ischemic events in neuroendovascular treatments by APAL system. | Tasuku Sakayori | |
| PB-209 | PB0209 - Valuable chromogenic assay to assess the efficacy of the reversal by Andexanet-alpha | CLAIRE DUNOIS | |
| PB-223 | PB0223 - CRYOFIBRINOGENEMIA: major role of fibrinogen and albumin synergism in increased soluble fibrin level | Dennis Galanakis | |
| PB-0230 | PB0230 - Elevated lipoprotein(a) links with fibrinolysis and valvular calcification in aortic stenosis | Anna Hojda | |
| PB-0243 | PB0243 - Length of ischaemia duration is associated with fibrin film coverage of acute myocardial infarction | Daniel Zaldumbide | |
| PB-0248 | HPB0248 - Monitoring response to therapeutic interventions in a patient with a fibrinolytic pathway defect | Maria Notini | |
| PB-0251 | PB0251 - Protein carbonylation as a modulator of fibrin clot properties in thyroid disorders | Anna Hojda | |
| PB-0269 | PB0269 - CLINICAL IMPLICATIONS OF HEMOPHILIA TREATMENT CENTERS IN DEVELOPING COUNTRIES | Emina Suljovic-Hadzimesic | |
| PB-0272 | PB0272 - Comparability of human and bovine cFVIII assay in mild haemophilia A with FVIII assay discrepancy. | Jireh Ann Batac | |
| PB-279 | PB0279 - Effectiveness and safety of damoctocog alfa pegol extended dosing regimens in hemophilia A | Amanda Ward | |
| PB-0280 | PB0280 - Effectiveness of emicizumab in hemophilia A: 4th interim analysis of the real-world study EMIIL | Petra Joestingmeyer | |
| PB-0286 | PB0286 - Factor activity bleeding phenotype and delivery outcomes in Hemophilia A and B carriers | Valerie Gao | |
| PB-0291 | PB0291 - Haemophilia in East Mediterranean: Trends in Prevalence and Treatment Use (2014-2022) | Abdulrahman Algarni | |
| PB-293 | PB0293 - HEM-POWR interim analysis of damoctocog alfa pegol in patients with hemophilia A in Canada | Amanda Ward | |
| PB-0296 | PB0296 - INHIBIT: A study of inhibitors and biomarkers in previously untreated Hemophilia A patients | Nicoletta Machin | |
| PB-0304 | PB0304 - Multidisciplinary Care and Quality of Life in Colombian Adults with Hemophilia: A Cross-Sectional Study | JUAN GUILLERMO DUQUE ORTEGA | |
| PB-0314 | PB0314 - Recombinant Activated Factor VIIa Combined with Tranexamic Acid Control Hemostasis in Patients with | Galia Spectre | |
| PB-0320 | PB0320 - Succesful repeated angiographic embolization of the genicular arteries in a patient with hemophilia B and an inhibitor | ANGELIKA BÁTOROVÁ | |
| PB-0330 | PB0330 - Why genotype? Results of a survey of U.S. providers utilizing a hemophilia A genotyping program | Greg Melroe | |
| PB-0344 | PB0344 - Bleeding and Thrombosis Risks with Danaparoid Sodium in HIT: A Retrospective Study | david smadja | |
| PB-0348 | PB0348 - Consistent Response to Avatrombopag for Pediatric ITP Across Various Baseline Characteristics | Scott Kolodny | |
| PB-0353 | PB0353 - Early initiation of TPO-RA reduces total corticosteroid dose in adult ITP:Japanese database analysis | Kodai Suzuki | |
| PB-354 | PB0354 - Early Platelet Count Indicators of Heparin-Induced Thrombocytopenia After Major Cardiac Surgery | Ishac Nazy | |
| PB-0356 | PB0356 - Effectiveness and safety of avatrombopag in ITP patients switching from eltrombopag or romiplostim | CRISTINA IZQUIERDO | |
| PB-0363 | PB0363 - Evaluation of a Chemiluminescent IgG Anti-PF4/H Assay for heparin-induced thrombocytopenia diagnosis | Nicolas Gendron | |
| PB-0364 | PB0364 - Evaluation of Efficacy and Safety of Avatrombopag in Children with ITP Based on Disease Duration | Scott Kolodny | |
| PB-0366 | PB0366 - FLORIO ITP MOBILE APP: A REVOLUTION IN ITP MONITORING. | Sara Montolío Chiva | |
| PB-0368 | PB0368 - GPVI is a receptor for the PF4/anti-PF4 IgG complex and mediates platelet activation in HIT | Ivo Francischetti | |
| PB-369 | PB0369 - Guideline on the Management of Critical Bleeding in Patients with Immune Thrombocytopenia | Donald Arnold | |
| PB-0373 | PB0373 - Immune thrombocytopenia and primary immunodeficiencies. Series of 6 cases. | CRISTINA PASCUAL- IZQUIERDO | |
| PB-384 | PB0384 - Pirtobrutinib in Adults with Immune Thrombocytopenia: A Phase 1/2 Dose-finding Study in Progress | Abby Atwater | |
| PB-0400 | PB0400 - Validation of a New Automated Chemiluminescent Immunoassay for the detection of anti-platelet factor 4/heparin (PF4/H) IgG antibodies | Lily Zhang | |
| PB-402 | PB0402 - Cancer-activated endothelial and cancer cells synergize to enhance thrombin generation in tumors | Mohammed Baghdadi | |
| PB-0403 | PB0403 - Circulating Tumour Cells alter vascular inflammation CD73 and cfDNA release in ovarian cancer | Lucy Norris | |
| PB-0407 | PB0407 - High-Sensitivity C-Reactive Protein and Fibrinogen for the Prediction of Thrombosis in Lung Cancer | Patricia Gomez Rosas | |
| PB-0428 | PB0428 - Analysis of Real-World Methods of Identifying Venous Thromboembolic Events in Patients with Cancer | Aysswarya Manoharan | |
| PB-0430 | PB0430 - Anticoagulation Management In Patients With Cancer-Associated Small Venous Thromboembolism | KOU ROGER | |
| PB-431 | PB0431 - Apixaban and tinzaparin reverse anticancer drug resistance caused by fibrin clot shields in tumors | Patrick Van Dreden | |
| PB-0439 | PB0439 - Catestatin and relaxin-2 in platelet activation and blood coagulation in venous thromboembolism | Oleksii Korzh | |
| PB-0442 | PB0442 - Circulating Vascular Endothelial Growth Factor Level in venous thromboembolic Disorder | Chandan Mohapatra | |
| PB-0447 | PB0447 - Coagulation biomarkers postoperative thromboembolism and survival in ovarian cancer | Lasse Myllylahti | |
| PB-0454 | PB0454 - Direct oral anticoagulant in thromboembolism prophylaxis after hip fracture surgery in Thai patients | Pitiphong Kijrattanakul | |
| PB-455 | PB0455 - Effects of human derived plasminogen on fibrinolytic activity in experimental murine venous thrombos | Satish Kumar Devarapu | |
| PB-0457 | PB0457 - Efficacy and safety of direct oral anticoagulants for treatment of cancer-associated venous thromboembolism: a real-life uruguayan registry | Ana Pizzarossa | |
| PB-0467 | PB0467 - Impact of body mass index on the utility of D-dimer in cancer patients with deep vein thrombosis | Tatsuya Konishi | |
| PB-470 | PB0470 - Implementation of Venous Thromboembolism Prophylaxis in Hospitals | Vishnu Prasad | |
| PB-0473 | PB0473 - Incidence of thromboembolic and bleeding events in a cohort of patients with unresectable hepatocellular carcinoma on systemic therapy | Elena Butera | |
| PB-0485 | PB0485 - Management of lesser saphenous vein thrombosis close to the saphenopopliteal junction: A UK Survey. | Kirollos Kamel | |
| PB-0492 | PB0492 - Prescription of pharmacological thromboprophylaxis in medical patients: Experience with 2 risk assessment models in two tertiary centres in Uruguay | Ana Pizzarossa | |
| PB-0493 | PB0493 - Prevalence and clinical associations of IgA antiphospholipid antibodies in APS and SLE | Maria Efthymiou | |
| PB-0505 | PB0505 - Safety of D-dimer testing to rule out pulmonary embolism in patients with cancer | Kristina Vrotniakaite-Bajerciene | |
| PB-0515 | PB0515 - Thromboembolism and Bleeding in Multiple Myeloma: Rates Risk Profiles and Thromboprophylaxis | Julia Riedl | |
| PB-0517 | PB0517 - Thrombosis risks in prostate cancer patients on oral anticoagulants and enzalutamide/apalutamide | Tzu-Fei Wang | |
| PB-0534 | PB0534 - Antithrombin replacement prior to delivery in pregnant women with hereditary antithrombin deficiency | Maria Teresa De Sancho | |
| PB-0537 | PB0537 - Bleeding Disorders and Obstetric Challenges: A Retrospective Analysis of a Majority Hispanic Cohort | Kamilia Moalem | |
| PB-0539 | PB0539 - Challenges in Pregnancy and Delivery for Women with Hemophilia and Carriers: a 10-Year Analysis | Mariasanta Napolitano | |
| PB-0543 | PB0543 - Comparison of Machine Learning classifiers for hypercoagulability associated risk of IVF failure. | Patrick Van Dreden | |
| PB-544 | PB0544 - Comparison of VTE prevention guidelines during hospitalization in pregnancy: cost-effectiveness. | VENINA BARROS | |
| PB-547 | PB0547 - D-dimer in Pregnancy Clinical Significance | Maria Hulikova | |
| PB-0554 | PB0554 - Factor IX levels Can Increase in Pregnancy in Carriers of Haemophilia B | Claire Kelly | |
| PB-0567 | PB0567 - Management of Antithrombin deficiency in pregnancyReview of 4 cases managed at Royal Free Hospital | Yawar Yaseen | |
| PB-0574 | PB0574 - Reproductive Tract Bleeding in Adolescent Females on Anticoagulation and/or Antiplatelet Therapy- A Systematic Review | Neeraja Swaminathan | |
| PB-588 | PB0588 - Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding | Christopher Czura | |
| PB-0590 | PB0590 - Uterine Bleeding in Patients with Venous Thrombosis and Association with Sex of Treating Clinician | Rachel Rosovsky | |
| PB-0601 | PB0601 - A Quarterly Audit to Assess Venous Thromboembolism Prevention Management in Hospital Inpatients | Mohamed Shaisha | |
| PB-0602 | PB0602 - A systematic review on anti-Xa monitoring in the therapeutic use of Low-Molecular-Weight Heparins | Nakisa Khorsand | |
| PB-0605 | PB0605 - An Audit to Assess Therapeutic Unfractionated Heparin (UFH) for Hospital Adult Inpatients | Mohamed Shaisha | |
| PB-0619 | PB0619 - Arterial Thromboembolism in Patients with Cancer-Associated Thrombosis: A Meta-Analysis | Cilomar Martins de Oliveira Filho | |
| PB-0624 | PB0624 - Clinical and Pharmacogenetic Analysis of DOACs in Elderly Patients with Frailty | Diego Servidio | |
| PB-625 | PB0625 - Clinical Outcomes of Venous Thromboembolism: Insights from Thailand GARFIELD-VTE Registry | Sithakom Phusanti | |
| PB-0629 | PB0629 - Comparison of inhibitory effects between FXIa inhibitors and DOACs in thrombin generation assay | Osamu Kumano | |
| PB-634 | PB0634 - Development of a Thrombin Generation Assay for the Assessment of Novel Factor XI Inhibitors | Beth Bouchard | |
| PB-0635 | PB0635 - Direct comparison of inhibitory effects by one-stage assay in factor XIa inhibitors | Osamu Kumano | |
| PB-0636 | PB0636 - Direct oral anticoagulants and telephonic follow-up consultations.The importance of Close Monitoring | Angel Horrillo Orejudo | |
| PB-638 | PB0638 - Dose escalation effects of intravenous APAC a heparin proteoglycan mimic in healthy participants | Riitta Lassila | |
| PB-657 | PB0657 - Implementation of Direct Oral Anticoagulant Perioperative Interruption Protocol | David Gimelfarb | |
| PB-0658 | PB0658 - Improving Safe Anticoagulant Prescribing with Prescriber-Pharmacist Partnership: A Randomized Trial | Geoffrey Barnes | |
| PB-0665 | PB0665 - Long term outcomes of a multicenter aspirin deprescribing intervention | Avilasha Sinha | |
| PB-0669 | PB0669 - New USP28 agonists and USP40 inhibitors with cardioprotective and antithrombotic effects | Aleksandr Samorodov | |
| PB-0673 | PB0673 - Patient Satisfaction with Anticoagulant Therapy for VTE. A Systematic Literature Review | Patrick Van Dreden | |
| PB-0675 | PB0675 - Pediatric Middle Cerebral Artery Stroke due to coil embolization: Anticoagulation Management | Alexander Hsu | |
| PB-676 | PB0676 - Periprocedural Anticoagulant Management: Computerized Decision Support System Concordance Testing | Amulya Bhagirath | |
| PB-0679 | PB0679 - Pharmacokinetics and Pharmacodynamics of Phosphodiesterase 4 Inhibition in a Low Flow ECMO Model | Andrew Meyer | |
| PB-0684 | PB0684 - Procoagulant state modulates the effect of direct oral anticoagulants in cirrhosis | Cindy Pereira Portela | |
| PB-0685 | PB0685 - Racial Disparities in Bleeding during Extended Anticoagulant Therapy for Venous Thromboembolism | Yan Xu | |
| PB-0687 | PB0687 - Reagent variability of APTT prolongation in factor XIa inhibitors of asundexian and milvexian | Osamu Kumano | |
| PB-0689 | PB0689 - Real-world utilisation of Andexanet-Alfa: A single centre experience | Niamh Loughran | |
| PB-0695 | PB0695 - Safety comparison of Direct Oral Anticoagulation among patients with AF & LV thrombus in KSA | Daniel Zaldumbide | |
| PB-0701 | PB0701 - The SYK inhibitor Bi 1002494 ively impairs thrombosis structure in a murine femoral artery ferric chloride-induced occlusion model without affecting puncture wound hemostasis structure | Brian Storrie | |
| PB-706 | PB0706 - Title: Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in the Management of Chronic Portal Vein Thrombosis in Cirrhotic Patients - A Retrospective Study | Gary Batra | |
| PB-0707 | PB0707 - Upper Extremity Superficial Venous Access in Ultrasound-Assisted Thrombolysis for Pulmonary Embolism | Ilham Benzidia | |
| PB-0715 | PB0715 - Analysis of clot properties via thromboelastography compared to plasma fibrin clot characteristics | Anna Hojda | |
| PB-0723 | PB0723 - Blood inflammatory factors as risk factors in the diagnosis of thrombotic thrombocytopenia purpura | XU YE | |
| PB-0725 | PB0725 - Clinical Outcomes of Genetic Panel Testing for Inherited Bleeding Disorders: Genomic MDT Case Review | Alan Mitchell | |
| PB-0732 | PB0732 - Disease-Specific Expertise for the Development of NGS Panels for Inherited Hemostatic Disorders | Julie Majerus | |
| PB-0736 | PB0736 - F8 variants in intron 1 may disrupt transcriptional enhancers causing haemophilia A. | Yohann JOURDY | |
| PB-0739 | PB0739 - Genetic test utilization for hemostatic disorders: experience of a reference laboratory | Christine Koellner | |
| PB-0743 | PB0743 - Impact of Extended Half-Life Factor VIII on Pharmacokinetics and Bleeding Rates in Hemophilia A | Natalia duque Zapata | |
| PB-0749 | PB0749 - Machine Learning Algorithms for Predicting Recurrent Thrombotic Events in Antiphospholipid Syndrome | Ana Marco-Rico | |
| PB-772 | PB0772 - A specific FX activator for bleeding episodes treatment in hemophilia with inhibitor | Ada Zhang | |
| PB-774 | PB0774 - Acquired Haemophilia A: Current Treatment and Outcomes in New South Wales Australia | Vickie Lee | |
| PB-778 | PB0778 - Addressing unmet medical needs and health inequities in haemophilia A: expert consensus statements | Tyrone Daniel | |
| PB-0779 | PB0779 - Advancing Hemophilia A Management with the Portability of Turoctocog Alfa Pegol (N8-GP) | Angel Horrillo Orejudo | |
| PB-792 | PB0792 - Cardiovascular safety of emicizumab in older patients: findings from a large unbiased cohort | Quentin Van Thillo | |
| PB-798 | PB0798 - Early emicizumab prophylaxis does not prevent FVIII inhibitor occurrence in MTP with severe HA | Tami Barazani Brutman | |
| PB-0803 | PB0803 - Efficacy of concizumab prophylaxis in patients with Hemophilia:A systematic review and meta-analysis | Bezalel Hakkeem | |
| PB-0809 | PB0809 - Emicizumab in Patients with Severe Haemophilia A without Inhibitors: A Single Center Experience | Monika Biernat | |
| PB-810 | PB0810 - Emicizumab provides excellent brain protection in a large unbiased retrospective cohort | Quentin Van Thillo | |
| PB-0811 | PB0811 - Establishment of a multicenter prospective observational bleeding disorders registry in Japan | Takeshi Matsumoto | |
| PB-0816 | PB0816 - Extravascular distribution of factor IX: evidence and relevance for hemophilia B replacement therapy | Liz Beatty | |
| PB-0822 | Final analysis of the phase 1/2 trial of valoctocogene roxaparvovec for severe hemophilia A | Gillian Clague | |
| PB-0823 | PB0823 - First Data from the American Thrombosis and Hemostasis Network Transcends Registry Hemophilia Gene Therapy Outcomes Arm | Janice Staber | |
| PB-0827 | PB0827 - Gene therapy for hemophilia: Survey on care team knowledge attitudes and preparedness | Melissa Glasner | |
| PB-828 | PB0828 - Gene Therapy in Hemophilia B: Innovative Methods to Evaluate Value Contribution | Isabel Cortés Lorenzo | |
| PB-0831 | PB0831 - Hemoglobin increase in children with hemophilia A on emicizumab: HAVEN 2 & 7 post hoc analysis | Phoebe Tate | |
| PB-0854 | PB0854 - Patient preferences for the treatments of hemophilia A and B in France. | Monia Ezzalfani | |
| PB-0857 | PB0857 - Persistent Musculoskeletal Challenges Despite Emicizumab Benefits in Adult Haemophilia A Patients | Cedric Hermans | |
| PB-0866 | PB0866 - Real world outcomes of acquired haemophilia A in 2025: An Australian single centre experience | PRATHEEPAN PUVANAKUMAR | |
| PB-868 | PB0868 - Real-World Effectiveness and Usage of Recombinant Factor IX Fc: Final Data from the B-MORE Study | Costello Medical | |
| PB-0869 | PB0869 - Real-world efficacy of concizumab prophylaxis in a patient with hemophilia B and inhibitors | Tefu Weng | |
| PB-0871 | PB0871 - Reduced cytokine release by dendritic cells upon binding of factor VIII immune complexes to FcyRIIb | Mariarosaria Miranda | |
| PB-0875 | PB0875 - Safety and efficacy of KN057 the first anti-TFPI monoclonal antibody in Chinese hemophilia patients | Mankai Ju | |
| PB-0877 | PB0877 - SPK-8011 vector genome maintains an active transcriptional state for up to 72 weeks in adult mice | Helen Miller | |
| PB-0881 | PB0881 - The impact of emicizumab on averted bleeds and hospitalization days in people with hemophilia A | Helen Miller | |
| PB-882 | PB0882 - The impact of severe nutritional vitamin K deficiency on emicizumab therapy | Philip Wright | |
| PB-0887 | PB0887 - WFH Gene Therapy Registry Governance: Advancing Global Research Collaboration & Patient Safety | Mayss Naccache | |
| PB-888 | PB0888 - WFH Living Guidelines Model The Process | Donna Coffin | |
| PB-0889 | PB0889 - A Diagnostic Challenge for UK NEQAS (Blood Coagulation) Proficiency Testing Participants | Ian Jennings | |
| PB-0893 | PB0893 - Do we need harmonisation in reporting haemostasis assay results to avoid errors? | Ian Jennings | |
| PB-0894 | PB0894 - EFA and EMI spiked samples for NEQASBC and ECAT FVIII exercise Autumn 2024 | christopher reilly-stitt | |
| PB-0895 | PB0895 - Efanesoctocog alfa measurement data from exercise between NEQAS & ECAT participants Autumn 2024. | christopher reilly-stitt | |
| PB-0901 | PB0901 - Monitoring and Adherence in LMICs: A PDSA-Based Quality Improvement Project Utilizing POCT INR Self-TestingOral - OR - Poster Presentation,PNS 02 - Poster networking session | Sumaira Khan | |
| PB-0902 | PB0902 - Nurse-Led Quality Improvement: Streamlining Workflow in a Multidisciplinary Thrombosis Service | Elise Moore | |
| PB-0903 | PB0903 - The generation gap to psychological difficulties in hemophilia carriers | tomie FUJII | |
| PB-0904 | PB0904 - The Psychological and Emotional Impact of VTE: Results from a Qualitative Patient-Oriented Study | Stephanie Young | |
| PB-0913 | PB0913 - Anticoagulation with rivaroxaban in pediatric oncology: a case series | Joyce C M Lam | |
| PB-0922 | PB0922 - Clinical Characteristics in Children with Isolated Low Von Willebrand Factor Collagen Binding Activity | Fernando Corrales-Medina | |
| PB-0943 | PB0943 - Identifying biomarkers of bleeding in babies undergoing cardiac surgery with cardiopulmonary bypass | Suelyn Van Den Helm | |
| PB-0946 | PB0946 - Improving Time to Factor Therapy for Patients with Bleeding Disorders in the Emergency Department | Arun Gurunathan | |
| PB-0950 | PB0950 - Local Experience with Subcutaneous Protein C Injection in Managing Homogeneous Protein C Deficiency. | Ohoud Kashari | |
| PB-0960 | PB0960 - Pediatric Venous Thromboembolism and Bleeding from Thromboprophylaxis: An International Survey | Robert Huibonhoa | |
| PB-965 | PB0965 - Post-Operative Antithrombosis Therapy for Congenital Cardiac Disease | Gregory Carlisle | |
| PB-0970 | PB0970 - Quebec Platelet Disorder in Ashkenazi Jews : The surprising genetic diagnosis | Dror Levin | |
| PB-0976 | PB0976 - Rivaroxaban levels monitorization in children: effect of age and weight on DOAC level | Ruben Berrueco | |
| PB-0980 | PB0980 - Safety/efficacy of pharmacologic prophylaxis in hospitalized adolescents with sickle cell disease | Vilmarie Rodriguez | |
| PB-0981 | PB0981 - Screening for Resistance to Activated Protein C Following Thrombosis in Young Patients | Marilyn Manco-Johnson | |
| PB-0982 | PB0982 - Scurvy in a child with autism spectrum disorder: a case report | Dáyrton Moreira | |
| PB-0983 | PB0983 - Successful pediatric endovascular thrombectomy in a case of infective endocarditis | Mark Grinberg | |
| PB-0986 | PB0986 - Systematic review on the management of hemostatic defects in children with liver disease | Bhavya Doshi | |
| PB-997 | PB0997 - Trends and Diagnostic Utility of PT and APTT in Coagulation Screens at a Tertiary Paediatric Centre | Gerard Gurumurthy | |
| PB-1001 | PB1001 - Whole-vial emicizumab dosing in pediatric hemophilia A: real-world data insights | Sonata Saulyte Trakymiene | |
| PB-1019 | PB1019 - Critical role for PP1 in megakaryocyte development signaling and hemostasis | Zoltan Nagy | |
| PB-1027 | PB1027 - Effect of human mesenchymal stem cell-derived platelet like cells on a GVHD model using NOG mice | Yumiko Matsubara | |
| PB-1035 | PB1035 - GP1BA-cre mice allow a strong recombination in pre Megakaryocyte-Erythroid progenitor. | Victor-Emmanuel Brett | |
| PB-1041 | PB1041 - Identification of genomic loci regulating the expression and release of (s)TLT-1. | Daniel Z | |
| PB-1042 | PB1042 - Identifying apoptosis and autophagy mechanisms in a megakaryocytic model of immune thrombocytopenia | Christina Bitsina | |
| PB-1044 | PB1044 - Influence of recombinant factor VIII binding to platelets on fibrin clot formation and stability | Greg Melroe | |
| PB-1049 | PB1049 - Loss of the Interaction Linking the &945;IIb Thigh Domain K514 to the &946;3 I-EGF2 domain E500 Leads to Constitutive &945;IIb&946;3 Activation | Lu Wang | |
| PB-1056 | PB1056 - Mitochondrial DNA Enhances Adrenaline-Induced Platelet Activation in Type-II Diabetes Mellitus | Durre Shehwar | |
| PB-1062 | PB1062 - Optimization Strategy for Rap1B-Targeting Single Domain Antibodies as Platelet Activation markers | maxime moulard | |
| PB-1066 | PB1066 - Plasma PF4 as biomarker for platelet reactivity and bleeding risk in cardiac surgery with DAPT | david smadja | |
| PB-1077 | PB1077 - Platelet products stored in plasma or additive solution differ in hemostatic function over storage | Jason Brandon | |
| PB-1078 | PB1078 - Platelet TLT-1 shedding in health in trauma patients or patients with haemostatic complications. | Amandeep Kaur | |
| PB-1096 | PB1096 - Unraveling the Composition of Aggregates in Cold-Stored Platelets | Irona Khandaker | |
| PB-1098 | PB1098 - Validation of a platelet storage device for research assays and point-of-care applications | Arnold Ju | |
| PB-1125 | PB1125 - Long-COVID patients exhibit continuing impairement of fibrinolysis | Tuukka Helin | |
| PB-1134 | PB1134 - Overt DIC scores in sepsis leukemia and solid cancer: a nation-wide database study in Japan | Takashi Ito | |
| PB-1147 | PB1147 - Serum levels of VEGF-A121 are associated with the disease severity of COVID-19 | Takayuki Ikezoe | |
| PB-1148 | PB1148 - Soluble P-Selectin and TXB2 but Not Circulating Cell-free DNA are diagnostic markers in HIT | Ivo Francischetti | |
| PB-1152 | A Comprehensive Assessment of the Impact of COVID Variant and Vaccination on Venous Thromboembolism and Mortality | Samuel Soff | |
| PB-1159 | PB1159 - Treatment of antiphospholipid-related libman-sacks endocarditis without systemic lupus erythematous. | Camille Durivage | |
| PB-1163 | PB1163 - Analysis of Thrombin and Activated Protein C in Venous Thrombosis at Atypical and Typical Sites | Heiko Ruehl | |
| PB-1166 | PB1166 - Clinician Recommendations for Post-Venous Thromboembolism Physical Activity: An International Survey | Anna Parks | |
| PB-1168 | PB1168 - Genetic analysis of patients with chronic thromboembolic pulmonary hypertension (CTEPH) | Zsuzsanna Bereczky | |
| PB-1174 | PB1174 - Non-invasive Imaging Accuracy in Portal Vein Thrombosis: A Systematic Review with Meta-Analysis | Laura Girardi | |
| PB-1185 | PB1185 - 4-factor prothrombin complex concentrate for warfarin reversal with LVADs: a meta-analysis | Luísa Roxo | |
| PB-1188 | PB1188 - Acquired Hemophilia A: insights from a 6-year experience in Liguria Italy | Angelo Claudio Molinari | |
| PB-1189 | PB1189 - An Audit to Assess Andexanet Alfa for Major Bleeding with Factor Xa Inhibitors | Mohamed Shaisha | |
| PB-1191 | PB1191 - Anticoagulation Management and Outcomes in Burns Patients | Mohamed Shaisha | |
| PB-1192 | PB1192 - Assessing the pro-hemostatic effect of CAY001 on thrombin generation and thromboelastography | Damien Kudela | |
| PB-1194 | PB1194 - Bleeding complications in patients with out-of-hospital cardiac arrest treated with cangrelor and oral P2Y12 inhibitors | Georg Gelbenegger | |
| PB-1199 | PB1199 - Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. | YOSHINOBU SEKI | |
| PB-1207 | PB1207 - Comparing trauma-induced coagulopathy in hip fracture surgery and elective hip arthroplasty: a thrombelastography study | Daniyya Chaudhry | |
| PB-1216 | PB1216 - Do Saudi Arabia Kingdom Patients Bleed Less than the Reported Average? | Daniel Zaldumbide. | |
| PB-1217 | PB1217 - Early Intra-operative Use of a Fibrinogen Concentrate in Patients Undergoing Major Abdominal Surgery | Eugenio Rosado | |
| PB-1219 | PB1219 - Efficacy and Safety of Fibrinogen Concentrate During Major Spinal Surgery: Phase 3 Randomized Trial | Eugenio Rosado | |
| PB-1224 | PB1224 - Evaluation of Hemostatic Function of Stored Whole Blood in Different Storage Solutions for 35 days | Susan Shea | |
| PB-1234 | PB1234 - Lupus anticoagulant interference in rotational thromboelastometry | Maximiliano Berro | |
| PB-1236 | PB1236 - Management of acquired hemophilia A with emicizumab / rituximab: insights from the Vienna experience | Paul Knöbl | |
| PB-1244 | PB1244 - PERFORMANCE OF DIC SCORING SYSTEMS & AT III FOR DIAGNOSIS OF DIC AND PREDICTION OF MORTALITY | ANJALI KELKAR | |
| PB-1249 | PB1249 - Post-discharge bleeding in medical patients: External validation of the Intermountain risk score | Mansour Gergi | |
| PB-1250 | PB1250 - Predicting Perioperative Bleeding in Hip Fracture Patients Using ISTH Criteria | Gareth Ryan | |
| PB-1251 | PB1251 - Prediction of Cold-Stored Platelet Function Using Baseline Metrics | Irona Khandaker | |
| PB-1256 | PB1256 - Rabbit Blood Banking: A Comparative Application for Transfusion | Lauren Jackson | |
| PB-1275 | PB1275 - Use of andexanet alfa for direct oral anticoagulant reversion: a retrospective study in a tertiary h | Iarossi Michael | |
| PB-1276 | PB1276 - Use of Fibrinogen Concentrate during Major Surgeries: Post-hoc Analysis of the Phase 3 AdFIrst Trial | Eugenio Rosado | |
| PB-1278 | PB1278 - VMX-C001 bypasses the effects of FXa-direct oral anticoagulants in healthy adults: ROTEM analysis | Tainá Gomes | |
| PB-1283 | PB1283 - Acquired factor V deficiency in China: clinical and laboratory features treatment and outcome | Mankai Ju | |
| PB-1293 | PB1293 - Autosomal Recessive Factor V Deficiency Caused by Three Novel Variants | Natalie Montanez | |
| PB-1298 | PB1298 - Citrullination in the C-terminus of TFPI-alpha impairs the inhibition of FV activation and of thrombin generation. | Rory Koenen | |
| PB-1300 | PB1300 - Clinical performance evaluation of a new system for FXI level determination: sthemO XI on sthemO 301 | Delphine Lavignasse | |
| PB-1301 | PB1301 - Coagulation activation during human liver transplantation is associated with intrinsic pathway activation | Fynn Elvers | |
| PB-1314 | PB1314 - Emicizumab-factor VIII association: impact on hemostasis tests and evaluation of hemostatic efficacy | Ladislas CAPDEVILA | |
| PB-1333 | PB1333 - Modifying Variants That Alone are Sufficient to Reduce Factor VII Levels | Diane Nugent | |
| PB-1337 | PB1337 - Mv-TF Procoagulant Phospholipid: Biomarkers of Severity in Hepatocellular Carcinoma and Cirrhosis | Patrick Van Dreden | |
| PB-1339 | PB1339 - Non-Severe Hemophilia A: Relationship Among Mutations Factor VIII Levels and Thrombin Generation | Ana Marco-Rico | |
| PB-1341 | PB1341 - Novel Variants in Fibrinogen Genes using a Customized 31-Gene Next-Generation Sequencing Panel | Diane Nugent | |
| PB-1342 | PB1342 - Optimizing Hemostasis in Factor XI Deficiency: The role of Prophylactic Plasma Exchange | Roshan Afshan | |
| PB-1343 | PB1343 - Parallelism in PT-based one stage extrinsic factor assays in normal subjects. | Susan Guy | |
| PB-1344 | PB1344 - Parallelism in PT-based one-stage extrinsic factor assays in patients receiving anticoagulants | Susan Guy | |
| PB-1364 | PB1364 - Tissue Factor-positive Microparticles and Risk of Thrombotic Complications in Sickle Cell Disease | Patrick Van Dreden | |
| PB-1365 | PB1365 - UK NEQAS BC-Activated partial thromboplastin time Mixing Study survey-An updated review | Anna Williams | |
| PB-1367 | PB1367 - Unravelling the role of coagulation factors in hemophilia A-associated bone metabolism | Jennifer Gebetsberger | |
| PB-1369 | PB1369 - Utility of screening tests to diagnose factor deficiencies and lupus anticoagulant | Shoshana Revel-Vilk | |
| PB-1371 | PB1371 - A novel p.C1130S mutation in a Finnish family with a complex phenotype of VWD | Timea Szanto | |
| PB-1372 | PB1372 - A novel pathogenic variant VWF-Cys2750Phe in CK domain caused type 2A VWD | Linhua Yang | |
| PB-1375 | PB1375 - A study of mood state using POMS2 in hemophilia patients | Aya Nakao | |
| PB-1378 | PB1378 - Age-Based Differences in Ankle Joint Damage Progression in Severe Hemophilia A Patients | Te-Fu Weng | |
| PB-1379 | PB1379 - Ageing related normalisation of Von Willebrand Factor - An Australian perspective | Fathima Ayyalil | |
| PB-1382 | PB1382 - Assessing the impact of the 2021 VWD guidelines on the diagnosis/management of low VWF patients | Michael Dong | |
| PB-1383 | PB1383 - Bleed experience in von Willebrand disease and validation of a Bleed and Medication Questionnaire | Helen Miller | |
| PB-1389 | PB1389 - Clinical characteristics and pathogenesis of 20 female haemophilia patients from Chinaa multi-cente | Linhua Yang | |
| PB-1391 | PB1391 - Clinical spectrum and treatment outcomes of Rare Bleeding Disorders in females | Kelly Davidson | |
| PB-1392 | PB1392 - Concern about falling in the ageing hemophilia population: a nationwide questionnaire study | Amal Abdi | |
| PB-1395 | PB1395 - Diagnosing Type 1 Von Willebrand disease using VWF:Act-to-FVIII Ratio: A retrospective study | Anshul Vagrecha | |
| PB-1397 | PB1397 - Effect of age on ISTH-BAT scores and type 1 VWD diagnosis in the Zimmerman program | Ferdows Atiq | |
| PB-1399 | PB1399 - Effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A by body mass index | Amanda Ward | |
| PB-1401 | PB1401 - Efficacy of Prophylactic Emicizumab in Type III Von Willebrand Disease Patients: A Two Case Reports | Ohoud Kashari | |
| PB-1403 | PB1403 - Evaluation of Interference Compromising Determination of VWF:GPIbM by INNOVANCE VWF Ac Assay | Andrew Podd | |
| PB-1408 | PB1408 - Factor-ONE-ing in surgery: survey of perioperative care for hereditary fibrinogenemias in the US | Nicoletta Machin | |
| PB-1412 | PB1412 - Genetic characteristics of patients with Factor XI deficiency | Rosa Sonja Alesci | |
| PB-1415 | PB1415 - HEAVY MENSTRUAL BLEEDING IN VON WILLEBRAND DISEASE: AN UNRECOGNISED PROBLEM IN CLINICAL EVALUATION | CRISTINA Pascual -Izquierdo | |
| PB-1419 | PB1419 - Impact of Cannabis on Joint Health in Hemophilic Patients on Extended Half-Life FVIII Prophylaxis | JUAN GUILLERMO DUQUE ORTEGA | |
| PB-1423 | PB1423 - Joint bleed diagnosis and treatment delays in people with hemophilia: Global real-world data | Sinead Stewart | |
| PB-1426 | PB1426 - Joint hypermobility is highly prevalent in a bleeding disorder referral population | Callie Berkowitz | |
| PB-1427 | PB1427 - Joint problems in female patients with haemophilia in 2024- still neglected | Rosa Sonja Alesci | |
| PB-1430 | PB1430 - Large Xq deletion including F8 and F9 with normal factor VIII and factor IX activity levels | Miguel Escobar | |
| PB-1433 | PB1433 - Longitudinal observation of pain status in a cohort of patients in a tertiary haemophilia centre | Katharina Holstein | |
| PB-1435 | PB1435 - Long-Term Secondary Factor VIII Prophylaxis in a Hemophilia A Mouse Model Lacking Inhibitor Response | Lara Monica | |
| PB-1436 | PB1436 - Lymphangiogenesis and iron clearance after hemarthrosis in FVIIIKO mice are FVIII dependent | Bilgimol Chumappumkal Joseph | |
| PB-1439 | PB1439 - Monitoring joint health in hemophilia patients in Spain: Updated analysis of the joint US project | Ibone Gonzalez | |
| PB-1457 | PB1457 - Prevalence of Synovitis in Patients with Haemophilia A: An interim report of the epidemiologic multicenter observational study | Marius Brühl | |
| PB-1462 | PB1462 - Quality of life in Bleeding Disorder of Unknown Cause vs. other mucocutaneous bleeding disorders | Callie Berkowitz | |
| PB-1464 | PB1464 - Rare Combined Congenital Bleeding Disorder- Bernard-Soulier and vWD | Joanna Larson | |
| PB-1466 | PB1466 - Real-world Recombinant Von Willebrand Factor Prophylaxis in Children with Von Willebrand Disease | Ciji Cabrera | |
| PB-1467 | PB1467 - Real-world Recombinant Von Willebrand Factor Prophylaxis in Type 1 or 2 Von Willebrand Disease | Ciji Cabrera | |
| PB-1468 | PB1468 - Regular physical activity improves quality of life of people with hemophilia: Ukrainian single center study in a real-life cohort | Tetiana Lymanets | |
| PB-1470 | PB1470 - Safety Assessment of a New Fibrinogen Concentrate in Patients with Congenital Fibrinogen Deficiency | Eugenio Rosado | |
| PB-1478 | PB1478 - The effect of concizumab on thrombin generation in FVII deficient plasma | Marianne Kjalke | |
| PB-1488 | PB1488 - Von Willebrand assay data from UKNEQASBC scheme 2010-2024 | christopher reilly-stitt | |
| PB-1489 | PB1489 - Von Willebrand Disease Aging and Bleeding Correlation (VWD ABC) Study | Craig Seaman | |
| PB-1490 | PB1490 - VWD Connect Foundation Severe Von Willebrand Disease Patient Registry: A Longitudinal Natural History and Patient Outcomes Study | Johnna Cesta | |
| PB-1493 | PB1493 - A family series of ACTN1-related thrombocytopaenia with an absent bleeding phenotype | Luke Attwell | |
| PB-1494 | PB1494 - A Novel ABCG8 Variant in Sitosterolemia: Impact on Platelet Function and Antithrombotic Therapy | ANA MARIN QUILEZ | |
| PB-1495 | PB1495 - A novel in-frame deletion in MYH9 gene in patient with macrothrombocytopenia | Yu Yan Carmen LEE | |
| PB-1498 | PB1498 - Absence of platelet dense granules and bleeding diathesis in Hermansky-Pudlak syndrome | Daniel Zaldumbide | |
| PB-1502 | PB1502 - Analysis of a case with thrombocytopenia and recurrent myocardial infarction | Xu Ye | |
| PB-1507 | PB1507 - Avatrombopag reduces platelet transfusion requirements in chemotherapy-induced thrombocytopenia | ASER ALONSO CARBALLO | |
| PB-1518 | PB1518 - Clinical history and management of Glanzmann Thrombasthenia: A retrospective chart review | George Morgan | |
| PB-1521 | PB1521 - Co-inheritance of LOF and GOF ITGB3 variants in Glanzmann Thrombasthenia: mechanistic studies | JOSE RIVERA POZO | |
| PB-1525 | PB1525 - Diagnostic Accuracy of a Semi-Automatic Microchip Flow Chamber for Platelet Function Disorders | David Schmidt | |
| PB-1529 | PB1529 - Dynamic Time-Course Analysis in Coagulation Profile Post rFVIIa Administration In Glanzman Patients | Ahmad Tarawah | |
| PB-1530 | PB1530 - Effectiveness of adjunctive caplacizumab treatment in immune thrombotic thrombocytopenic purpura | Gabriele Sapuppo | |
| PB-1534 | PB1534 - Establishing a Refence Interval for the Ratio of GPIb/IX and GPIIb/IIIa Expression by Flow Cytometry | Juliana Perez Botero | |
| PB-1539 | PB1539 - Genophenotypic Study of Patients with Suspected Inherited Platelet Disorders: Mayo Clinic Experience | Dong Chen | |
| PB-1545 | PB1545 - Impact of Iron Deficiency Anaemia & Heavy Menstrual Bleeding in Glanzmann Thrombasthenia | George Morgan | |
| PB-1565 | PB1565 - Pathogenicity assessment of a Novel RUNX1 Variant Drives Early FPDMM Diagnosis and Management | ANA MARIN | |
| PB-1569 | PB1569 - Platelet Electron Microscopic Dense Granule Analysis: A Multiyear Study Through Proficiency Testing | Dong Chen | |
| PB-1592 | PB1592 - UKNEQAS (Blood Coagulation) launches pilot Platelet Glycoprotein exercise May 2024. | christopher reilly-stitt | |
| PB-1594 | PB1594 - Unveiling the Unmet Need in Glanzmann Thrombasthenia: Insights from the ATHN Transcends GT Module Natural History Study | Divyaswathi Citla - Sridhar | |
| PB-1596 | PB1596 - Whole blood impedance aggregometry to assess the haemostatic potential of platelets post-transfusion | Fergal McGlynn | |
| PB-1598 | PB1598 - A new prototype automated assay measuring microvesicles tissue factor-dependent FXa generation | Loris Vallier | |
| PB-1599 | PB1599 - An international collaboration to characterize thrombotic events in TEMPI Syndrome | Graham Parker | |
| PB-1606 | PB1606 - Coagulation profile of convalescent plasma donors and recipients | Riitta Lassila | |
| PB-1630 | PB1630 - IMPAIRED ENDOTHELIAL FUNCTION AND ANGIOGENESIS IN GLANZMANN THROMBASTHENIA | Loredana Bury | |
| PB-1631 | PB1631 - IMPAIRED ENDOTHELIAL FUNCTION AND ANGIOGENESIS IN HERMANSKY-PUDLAK SYNDROME (HPS) TYPE 1 | Loredana Bury | |
| PB-1671 | PB1671 - Thrombin generation and fibrin clot structure in nephrotic patients with primary glomerular disorder | Alessandro Casini | |
| PB-1676 | PB1676 - Treatment and outcomes of subclinical valve thrombosis after transcatheter aortic valve replacement | Julia Sharobim | |
| PB-1677 | PB1677 - Trends in Mortality Due to Disseminated Intravascular Coagulation in the United States: Geographic and Metropolitan Area Disparities from 1999-2020 | Fatima Tuz Zahra | |
| PB-1678 | PB1678 - Unlocking Vasculogenic Stem Cell ontogeny: Image Cytometry Differentiates CD34 and CD133 Profiles | david smadja | |
| PB-1683 | PB1683 - Acute care utilization in antiphospholipid syndrome and/or systemic lupus erythematosus | Leslie Skeith | |
| PB-1693 | PB1693 - Clinical Impact of the Integrated Testing Algorithm for the Detection of a Lupus Anticoagulant | Neel Hegde | |
| PB-1694 | PB1694 - Clinical utility of thrombin generation in patients with thrombophilia | Kristina Vrotniakaite-Bajerciene | |
| PB-1698 | PB1698 - COMPARISON of three strategies for pulmonary embolism diagnosis : a randomized controlled trial | Romain Le Pennec | |
| PB-1707 | PB1707 - HERDOO2 rule to identify unprovoked VTE women who can discontinue: Can I use Non-Vidas D-Dimer? | Harika Dasari | |
| PB-1711 | PB1711 - Impact of baseline thrombocytopenia on early outcomes in patients with acute venous thromboembolism | Manuel Monreal | |
| PB-1713 | PB1713 - Impact of Pulmonary Hypertension on hospitalization outcomes in patients with Myeloproliferative Neoplasms | Nikhil Vojjala | |
| PB-1716 | PB1716 - Inherited thrombophilia and persistent left ventricular thrombus after myocardial infarction | Anna Hojda | |
| PB-1727 | PB1727 - Mortality Prediction in Acute Pulmonary Embolism Through AI-Powered Electrocardiogram Analysis | Damon Houghton | |
| PB-1734 | PB1734 - Platelet hyperaggregability is not present in patients with inherited thrombophilia and thrombosis. | Petr Kessler | |
| PB-1740 | PB1740 - Safety and Efficiency of PE Diagnostic Strategies in Patients with Chronic Lung Disease: an IPDMA. | Vicky Mai | |
| PB-1743 | PB1743 - Temporal Dynamics of Extracellular Vesicles in Two Patients with Severe COVID-19 | Gabriel Dumitrescu | |
| PB-1744 | PB1744 - Temporal patterns of venous thromboembolism incidence and mortality in Finland | Lasse Myllylahti | |
| PB-1747 | PB1747 - The patients with venous thromboembolism with and without the history of a previous arterial event are there any differences? | Jana Hirmerová | |
| PB-1753 | PB1753 - Thrombosis in antiphospholipid syndrome patients after nearly 1000 patient-years of follow-up | Gustavo Balbi | |
| PB-1756 | PB1756 - Time Trends in All-Cause Mortality After First-Time Pulmonary Embolism in Adults Aged 1849 Years | Katarina Glise Sandblad | |
| PB-1761 | PB1761 - Utility of PT and Anti-Xa to complement anticoagulation screening in Lupus Anticoagulation testing | Jesse Qiao | |
June 21-25, Washington

Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|
|